Jason Park

Bioengineer, Entrepreneur
CEO @Empress_Tx
Partner @FlagshipPioneer

[Empress Therapeutics @Empress_Tx]

𝗛𝘆𝗽𝗲 𝗼𝗿 𝗛𝗼𝗽𝗲? Empress CSO Murray McKinnon weighs in on whether he thinks AI is truly transforming drug development in this @pharmasalmanac Q&A.

🔗 https://t.co/F1r7asbtAy

[Empress Therapeutics @Empress_Tx]

If there’s a problem you care about, go solve it. That's the advice of Shannon McArdel, our Director of Immunology, whose mother's struggle with a progressive, debilitating disease motivated her to pursue a career in science. For #IDWGS, she shares her journey and advice for those who also want to succeed in STEM.

#TeamEmpress #CareersinSTEM #WomeninSTEM #WomenInScience

[Empress Therapeutics @Empress_Tx]

Meryl Kelada comes from a long line of physicians & scientists, and her biochemist grandmother helped spark her curiosity in science from a young age. Now a chemical biologist herself, Meryl shared her advice for other aspiring #WomeninScience for #IDWGS.

#TeamEmpress #CareersinSTEM #WomeninSTEM

[Jason Park @parkocity]

When it comes to #AI in #drugdiscovery, human clinical data and metagenomics is a great starting point. This Q&A explains how @Empress_Tx uses #machinelearning to identify new molecular entities that hold promise as novel medicines for many diseases.

#Chemilogics

[Empress Therapeutics @Empress_Tx]

Medicine designed within the context of a patient’s disease? It sounds straightforward, but the reality is far more complex. SVP of Biology Joe Kelleher talks to @DrugDiscovNews about how Empress is using AI and machine learning—anchored in human clinical data and genetic chemistry—to make unexpected connections to human diseases and clinical indications that were not previously appreciated.

📚 Read the Q&A: https://t.co/3HlkVunZFi

#Chemilogics #smallmolecule #drugdiscovery #AI #machinelearning #microbiome

[Jason Park @parkocity]

Proud to share how Empress is transforming drug discovery with our  #Chemilogics platform at #FlagshipJPM’s CEO Chat! From faster timelines to lower risk, we’re unlocking new possibilities in small molecule drug discovery. Excited for what’s ahead!

#FlagshipFounded #JPM25

[Empress Therapeutics @Empress_Tx]

At the #FlagshipJPM CEO Chat, Empress CEO @parkocity shared how the company’s #Chemilogics platform is rewriting the rules of small molecule drug discovery.

🔬 Platform Differentiation: Empress combines genetics, co-evolution, AI, and synthetic biology to decode how DNA programs chemical synthesis. Starting with drug-like compounds already present in the body, we solve the key challenges of target identification, indication selection, and toxicology right from the start.

⚙️ Technology & Efficiency: With access to Nature’s “evolutionary database,” Empress has reduced drug discovery timelines to just two years from program conception to candidate. Leveraging human #metagenomics to find drug-like leads is faster and smarter.

💊 Pipeline Progress: Three first-in-class immunology programs are moving toward the clinic, with one already partnered. With hundreds of potential programs in the pipeline, 2025 promises big moves!

📈 Clinical Success: With a 50% in vivo success rate and clean tox profiles, Empress’ human-first data-driven approach has the potential to significantly reduce clinical development risks.

🤝 Teamwork: Backed by a powerhouse team that previously helped advance 30+ clinical programs and nine marketed products, Empress is focused on maximizing its pipeline's potential.

Watch the short interview in the @FlagshipPioneer Studios below or on YouTube: https://t.co/ed16Z76lhP

#JPM25 #FlagshipFounded #smallmolecule #drugdiscovery #geneticchemistry #AI #machinelearning #synbio

[Jason Park @parkocity]

We’re entering a new era of #polyintelligence. @Empress_Tx combinines human, machine, and nature’s intelligence to transform small molecule drug discovery.

Learn more in @NoubarAfeyan’s annual letter and in this special section: https://t.co/pNX1xyZYk0

#JPM25 #FlagshipJPM

[Flagship Pioneering @FlagshipPioneer]

Read or listen to Flagship Pioneering’s 2025 Annual Letter in which Founder & CEO @NoubarAfeyan explores polyintelligence — the synthesis of human, machine, and nature's intelligence, and how it is driving a new renaissance in science and technology: https://t.co/HeiyQYlDJe

Drawing inspiration from Leonardo da Vinci's integrated thinking, Noubar discusses how artificial intelligence will enhance our understanding of nature's adaptive genius in unprecedented ways. He highlights breakthroughs in biotechnology, agriculture, and machine intelligence, and how these polyintelligent innovations can tackle multifaceted challenges in health, climate, and beyond.

And for more on how polyintelligence is informing and guiding Flagship’s work, dive into our newly launched Special Section: https://t.co/rB2OUf2xJA

#BiggerLeaps #FlagshipStudio #JPM25

[Flagship Pioneering @FlagshipPioneer]

Read or listen to Flagship Pioneering’s 2025 Annual Letter in which Founder & CEO @NoubarAfeyan explores polyintelligence — the synthesis of human, machine, and nature's intelligence, and how it is driving a new renaissance in science and technology: https://t.co/HeiyQYlDJe

Drawing inspiration from Leonardo da Vinci's integrated thinking, Noubar discusses how artificial intelligence will enhance our understanding of nature's adaptive genius in unprecedented ways. He highlights breakthroughs in biotechnology, agriculture, and machine intelligence, and how these polyintelligent innovations can tackle multifaceted challenges in health, climate, and beyond.

And for more on how polyintelligence is informing and guiding Flagship’s work, dive into our newly launched Special Section: https://t.co/rB2OUf2xJA

#BiggerLeaps #FlagshipStudio #JPM25

[Empress Therapeutics @Empress_Tx]

This holiday season, we’re toasting to the incredible team behind Empress Therapeutics! 🥂 We’re so proud to work alongside such innovative, passionate, and talented individuals.

Here’s to a joyful holiday season and a groundbreaking year ahead!

[Empress Therapeutics @Empress_Tx]

How is the pharmaceutical industry integrating innovations from adjacent industries or markets to enhance drug development and production?

Empress Co-Founder and Chief Innovation Officer Sabrina Yang, says: just as generative #AI applications like ChatGPT have transformed the interpretation and manipulation of language, pharma companies can use #machinelearning to interpret and manipulate the language of life – the genetic code – to discover new targets and medicines.

Sabrina explains more in this @pharmasalmanac roundtable: https://t.co/9rSf4rd83i

#Chemilogics #smallmolecule #pharma #drugdiscovery

[Empress Therapeutics @Empress_Tx]

Is it time to extend the central dogma of biology (i.e. DNA ➡️ RNA ➡️ proteins) to chemistry to include small molecule products of proteins?

Yes, argues Empress CEO Jason Park @parkocity in this @DDWJournal editorial, where he advocates for searching the human metagenome to discover drug-like molecules, and explains how Empress is combining medicinal chemistry with AI, machine learning & synthetic biology, to tap into the eons’ worth of evolutionary experimental data encoded within.

Read the article here: https://t.co/EqrUlxHoLz

#Chemilogics #smallmolecule #drugdiscovery #AI #machinelearning #synbio

[Empress Therapeutics @Empress_Tx]

Where ChatGPT goes from text to text, the Empress Chemilogics™ platform takes us from the code of DNA to chemistry, by way of the enzymes involved in chemical synthesis and modification.

In this excellent @EPM_magazine interview, Empress SVP of Drug Discovery Kevin Kreutter explains exactly how the company is harnessing #AI and #machinelearning to accelerate #smallmolecule #drugdiscovery.

🔗https://t.co/tFDJ6uWWn6

[Empress Therapeutics @Empress_Tx]

Could AI change the paradigms of drug discovery? Definitely, argues Empress co-founder & CIO Sabrina Yang. Not only can it drive speed and cost savings, #AI is already enabling things that were not possible before, such as directly predicting chemical structures from DNA sequences.

📺 Watch her panel discussion at @GenBIO's 𝗧𝗵𝗲 𝗦𝘁𝗮𝘁𝗲 𝗼𝗳 𝗔𝗜 𝗶𝗻 𝗗𝗿𝘂𝗴 𝗗𝗶𝘀𝗰𝗼𝘃𝗲𝗿𝘆 𝗦𝘂𝗺𝗺𝗶𝘁 𝟮𝟬𝟮𝟰: https://t.co/cdIB4dKE1l

📚 Read a summary: https://t.co/S4HSqMaD6L

[Empress Therapeutics @Empress_Tx]

We are excited to share that Empress Therapeutics has been named to @cenmag’s annual list of #10StartUpsToWatch! This recognition highlights our unique #Chemilogics platform that applies the power of genetics to access a previously untapped universe of chemistry-based drug leads inside the human body – bringing certainty and speed to small molecule drug discovery.

See more here: https://t.co/QPkvr6A0Jf

#smallmolecule #drugdiscovery #AI #machinelearning #synbio #metagenomics

[Empress Therapeutics @Empress_Tx]

Context matters when it comes to microbial communities in our bodies, especially in the gut. Different diets and other lifestyle factors can impact whether a person responds to probiotics and other treatments. We learned a lot from @FrancescaGazza5, who joined us at Empire HQ for the latest #EMPIREexternal talk.

The assistant professor at @Harvardmed, @MGHCancerCenter, and @MGHPathology shared her insights into the role of the gut #microbiome on immune function in #cancer.

🎥 See what she had to say in this short video.

[Empress Therapeutics @Empress_Tx]

Being a pioneer in your field comes with certain challenges. Just like innovations in recombinant DNA were required to unlock the generation of biologic protein-based drugs, we've had to invent new synthetic biology tools and methods to facilitate our access to a previously untapped universe of chemistry-based drug leads inside the human body.

In this interview with @BioPharmReport, Empress's Head of Platform Development, Dawn Thompson, discusses overcoming the challenges involved in exploring the metagenome for new medicines, as well as its exciting potential.

Read the Q&A here: https://t.co/yV8s669di8

#Chemilogics #smallmolecule #drugdiscovery #AI #machinelearning #synbio #metagenomics

[Jason Park @parkocity]

This Emerging Company profile for @PharmaScrip showcases how far Empress has come! It’s been an amazing first year, and I can’t wait to see what we will continue to accomplish. A big shout out to #TeamEmpress for all your hard work!

[Empress Therapeutics @Empress_Tx]

Combining the versatility of small molecules with the programmability of biologic therapies, Empress is creating a recipe for novel #drugdiscovery inspired by the chemistry in our bodies.

Learn more in this @PharmaScrip Emerging Company profile: https://t.co/ThOXfbjgMV

#Chemilogics #AI #smallmolecule #FlagshipFounded

[Empress Therapeutics @Empress_Tx]

Combining the versatility of small molecules with the programmability of biologic therapies, Empress is creating a recipe for novel #drugdiscovery inspired by the chemistry in our bodies.

Learn more in this @PharmaScrip Emerging Company profile: https://t.co/ThOXfbjgMV

#Chemilogics #AI #smallmolecule #FlagshipFounded

[Empress Therapeutics @Empress_Tx]

There's nothing better than evolution to inform scientists about what works, through experiments of nature conducted over eons. We share Steven Gygi's excitement about the potential for harnessing insights from the medicinal chemists inside our bodies, and we were delighted to welcome the cell biologist and proteomics pioneer as a guest speaker for the #EMPIREexternal seminar series.

The @Harvardmed professor of @GygiLab and Director of the Thermo Fisher Scientific Center for Multiplexed Proteomics spoke about his work creating a genome-scale map of the protein-protein interaction landscape in cells. We caught up with him afterwards for further insights into new technologies to better understand small molecule mechanisms of action.

🎥 See what he had to say in this short video.

#smallmolecule #drugdiscovery #AI #machinelearning #chemistry #computationalbiology #Chemilogics #microbiome #microbiology #BioPlex #proteomics

[Empress Therapeutics @Empress_Tx]

#TeamEmpress volunteered at The Greater Boston Food Bank. Thanks @Gr8BosFoodBank for all the work you do to provide healthy food and resources needed to thrive and end hunger across Eastern Massachusetts.

#GivingBack #CompanyCulture #EndHungerHere

[Empress Therapeutics @Empress_Tx]

The biosynthetic genes in our metagenome are equivalent in size to roughly 50% of the human genome. That's about a meter of non-human genetic DNA inside of us waiting to be decoded and turned into potential medicines.

Empress co-founder and CIO Sabrina Yang discusses using genetic chemistry in humans for drug discovery in this excellent interview with @dslevine for The Bio Report.

Listen to the podcast here: https://t.co/0UFJnRkx8S

#Chemilogics #smallmolecule #drugdiscovery #AI #machinelearning #microbiome #drugdiscovery